Valproic acid as a potentiator of metabolic syndrome in institutionalized residents on concomitant antipsychotics: Fat chance, or slim to none?

P and T

Volumn 40, Issue 2, 2015, Pages 126-132

  Zuo, Silu ^a   Fries, Brant E ^b,c,d   Szafara, Kristina ^e   Regal, Randolph ^e,f  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c Geriatric Centers of the UM School of Medicine   (United States)

^d GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f UM College of Pharmacy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOXAPINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE; VALPROIC ACID; ZIPRASIDONE;

ADULT; AGED; ARTICLE; BODY MASS; CHILD; COGNITION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; ETHNICITY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFANT; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEWBORN; VERY ELDERLY; WEIGHT GAIN;

EID: 84922771028     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs2002;16(10):695–714.
2. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord2013;15(1):1–44.
3. Product information: Depakene oral capsules, oral solution, valproic acid oral capsules, oral solution. North Chicago, Illinois; AbbVie Inc.; 2013.
4. Belcastro V, D’Egidio C, Striano P, Verrotti A. Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res2013;107(1–2):1–8.
5. Chang HH, Yang YK, Gean PW, et al. The role of valproate in metabolic disturbances in bipolar disorder patients. J Affect Disord2010;124(3):319–323.
6. Grundy SM, Brewer HB Jr., Cleeman JI, et al. Defnition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientifc issues related to defnition. Circulation2004;109(3):433–438.
7. Nihalani N, Schwartz TL, Siddiqui UA, Megna JL. Weight gain, obesity, and psychotropic prescribing. J Obes 2011;2011:893629.
8. Schwartz TL, Nihalani N, Jindal S, et al. Psychiatric medication-induced obesity: a review. Obes Rev2004;5(2):115–121.
9. Salvi V, Albert U, Chiarle A, et al. Metabolic syndrome in Italian patients with bipolar disorder. Gen Hosp Psychiatry2008;30(4):318-323.
10. McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry2002;63 (3):207–213.
11. Verrotti A, D’Egidio C, Mohn A, et al. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev2011;12(5):e32–e43.
12. Verrotti A, Manco R, Agostinelli S, et al. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia2010;51(2):268–273.
13. Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism1992;41 (6):666–670.
14. World Health Organization. The Anatomical Therapeutic Chemical Classifcation System with Defned Daily Doses (ATC/DDD). 2013. Available at: http://www.who.int/classifcations/atcddd/en. Accessed October 18, 2013.
15. Elmslie JL, Porter RJ, Joyce PR, et al. Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. Aust N Z J Psychiatry2009;43(1):53-60.
16. Kanemura H, Sano F, Maeda Y, et al. Valproate sodium enhances body weight gain in patients with childhood epilepsy: a pathogenic mechanisms and open-label clinical trial of behavior therapy. Seizure 2012;21 (7):496-500.
17. El-Khatib F, Rauchenzauner M, Lechleitner M, et al. Valproate, weight gain and carbohydrate craving: a gender study. Seizure 2007;16(3):226–232.